KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Royalty Pharma (RPRX) EBITDA: 2019-2025

Historic EBITDA for Royalty Pharma (RPRX) over the last 7 years, with Sep 2025 value amounting to $427.2 million.

  • Royalty Pharma's EBITDA fell 41.89% to $427.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.5 billion, marking a year-over-year decrease of 0.72%. This contributed to the annual value of $1.3 billion for FY2024, which is 13.38% down from last year.
  • Royalty Pharma's EBITDA amounted to $427.2 million in Q3 2025, which was up 103.60% from $209.8 million recorded in Q2 2025.
  • Over the past 5 years, Royalty Pharma's EBITDA peaked at $735.1 million during Q3 2024, and registered a low of -$482.7 million during Q4 2022.
  • Moreover, its 3-year median value for EBITDA was $361.5 million (2024), whereas its average is $359.6 million.
  • Its EBITDA has fluctuated over the past 5 years, first tumbled by 414.60% in 2022, then spiked by 824.08% in 2025.
  • Over the past 5 years, Royalty Pharma's EBITDA (Quarterly) stood at $153.4 million in 2021, then slumped by 414.60% to -$482.7 million in 2022, then surged by 226.98% to $612.9 million in 2023, then plummeted by 41.02% to $361.5 million in 2024, then crashed by 41.89% to $427.2 million in 2025.
  • Its last three reported values are $427.2 million in Q3 2025, $209.8 million for Q2 2025, and $534.2 million during Q1 2025.